Compare Abeona Therapeutics Inc (ABEO) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Xylem, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Xylem, Inc. trades at $118.32 (market cap $28.68B). The key difference: Xylem, Inc. is far larger — about 76.8× Abeona Therapeutics Inc's market cap, and Xylem, Inc. pays a 1.43% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | XYL | |
|---|---|---|
Market Cap | $373.32M | $28.68B |
Sector | Health | Industrials |
52-Week High | $7.23 | $152.95 |
52-Week Low | $4.17 | $106.34 |
Enterprise Value | $228.22M | $29.93B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Xylem (XYL) trades at $120.65, up 2.14% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin improving to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing its position in water technology solutions.
The stock offers upside to the $153.14 consensus price target, driven by steady earnings growth and margin expansion. Risks include execution challenges in a competitive market and potential macroeconomic headwinds affecting industrial demand. Analyst sentiment is mixed but leans positive with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
